sodium 1-amino-4-((2-ethylphenyl)amino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate | 1007600-03-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: sodium 1-amino-4-((2-ethylphenyl)amino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
• 英文别名: Sodium;1-amino-4-(2-ethylanilino)-9,10-dioxoanthracene-2-sulfonate
• CAS: 1007600-03-4
• 化学式: C₂₂H₁₇N₂O₅S*Na
• 分子量: 444.443
• InChiKey: CVJDIBOZSPIVKU-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  0.26
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  138
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  sodium 1-amino-4-((2-ethylphenyl)amino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 在 盐酸 、 水 、 sodium nitrite 、 乙醇 、 锌 作用下， 反应 0.01h， 以87%的产率得到4-(2-ethylphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid
  参考文献：
  名称：

  Efficient and mild deamination procedure for 1-aminoanthraquinones yielding a diverse library of novel derivatives with potential biological activity

  摘要：

  A convenient in situ method is described for reductive removal of the amino group in position 1 of the anthraquinone (AQ) moiety. The reaction proceeds smoothly within a few minutes yielding novel AQ derivatives in excellent yields. Diazonium salt formation is followed by reduction with zinc in ethanol. The method has been applied to a variety of 1-amino-AQ derivatives. It allows access to a large library of new AQ derivatives which possess potential as pharmacological tools for studying purinergic signaling, and as potential drugs, for example, for the treatment of cancer and cardiovascular diseases. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2012.09.011
• 作为产物：
  描述：

  2-乙基苯胺 、 sodium 1-amino-4-bromoanthraquinone-2-sulfonate 在 铜 作用下， 以 aq. phosphate buffer 为溶剂， 生成 sodium 1-amino-4-((2-ethylphenyl)amino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
  参考文献：
  名称：

  肺炎军团菌细菌外切核苷酸酶Lp1NTPDase的抑制剂。

  摘要：

  嗜肺军团菌是军团菌属的一种好氧性革兰氏阴性细菌，它是军团菌病的主要病原体。最近，鉴定了一种来自嗜肺乳杆菌的核苷三磷酸二磷酸水解酶（NTPDase），并将其称为Lp1NTPDase。它被发现是哺乳动物NTPDase的结构和功能同源物，可催化ATP水解为ADP和ADP水解为AMP。据信其活性有助于肺炎军团菌的毒性。因此，Lp1NTPDase抑制剂被认为是新型抗菌药物。但是，到目前为止，只有弱效化合物可用。在本研究中，建立了用于监测Lp1NTPDase活性的基于毛细管电泳（CE）的酶法。酶促反应在试管中进行，然后通过CE分离底物和产物，随后通过UV分析进行定量。在对该酶进行动力学表征后，研究了一系列与蒽醌染料活性蓝2（一种非选择性ecto-NTPDase抑制剂）结构相关的1-氨基-4-芳基（烷基）基氨基-2-磺基蒽醌衍生物的抑制活性。使用基于CE的酶测定法检测Lp1NTPDase的表达。在1-氨

  DOI：

  10.1016/j.bmc.2016.07.027

文献信息

• Development of Potent and Selective Antagonists for the UTP-Activated P2Y₄ Receptor
  作者：Muhammad Rafehi、Enas M. Malik、Alexander Neumann、Aliaa Abdelrahman、Theodor Hanck、Vigneshwaran Namasivayam、Christa E. Müller、Younis Baqi

  DOI：10.1021/acs.jmedchem.7b00030

  日期：2017.4.13

  nM, selectivity versus other P2Y receptor subtypes, and is thought to act as an allosteric antagonist. A receptor homology model was built and docking studies were performed to analyze ligand–receptor interactions. Compound 64 (PSB-1699, sodium 1-amino-4-[4-(3-pyridin-3-ylmethylthio)phenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate) represents the most selective P2Y4 receptor antagonist known

  P2Y 4是由尿苷5'-三磷酸（UTP）激活的Gq蛋白偶联受体，在体内，例如在肠，心脏和脑中广泛表达。到目前为止，尚未描述选择性P2Y 4受体拮抗剂。因此，我们开发和优化了基于蒽醌支架的P2Y 4受体拮抗剂。通过基于荧光的测定法评估效价，该测定法测量了稳定转染了人P2Y 4受体的1321N1星形细胞瘤细胞中UTP诱导的细胞内钙释放的抑制作用。本系列中最有效的化合物，钠1-氨基-4- [4-（2,4-二甲基苯硫基）苯基氨基] -9,10-二氧代-9,10-二氢蒽-2-磺酸盐（PSB-16133，61）表现出233 nM的IC 50值，相对于其他P2Y受体亚型具有选择性，并被认为是一种变构拮抗剂。建立了受体同源性模型，并进行了对接研究以分析配体-受体的相互作用。化合物64（PSB-1699，1-氨基-4- [4-（3-吡啶-3-基甲硫基）苯基氨基] -9,10-二氧代-9,10-二氢蒽-2-磺
• [EN] ANTHRAQUINONE COMPOUNDS AND THEIR USES<br/>[FR] COMPOSÉS D'ANTHRAQUINONE ET LEURS UTILISATIONS
  申请人：DUNDALK INST OF TECHNOLOGY

  公开号：WO2012035122A1

  公开（公告）日：2012-03-22

  The present invention relates to a compound comprising a substituted or unsubstituted anthraquinone, or a salt or isomer thereof, for use in treating a disorder caused by or associated with dysfunctional ion channel activity. The invention finds utility in the treatment of disorders associated with smooth muscle tone and contraction, such as arterial hypertension; myocardial infarction; faecal incontinence; constipation; gastro oesophageal reflux; impaired gastrointestinal passage; urinary incontinence; erectile dysfunction; and asthma.

  本发明涉及一种包含取代或未取代蒽醌，或其盐或异构体的化合物，用于治疗由或与离子通道活性失调有关的疾病。该发明在治疗与平滑肌张力和收缩有关的疾病方面具有实用性，如动脉高血压；心肌梗死；大便失禁；便秘；胃食管反流；胃肠道通行受阻；尿失禁；勃起功能障碍；和哮喘。
• Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists
  作者：Stefanie Weyler、Younis Baqi、Petra Hillmann、Marko Kaulich、Andrea M. Hunder、Ingrid A. Müller、Christa E. Müller

  DOI：10.1016/j.bmcl.2007.10.082

  日期：2008.1

  A library of anilinoanthraquinone derivatives was synthesized by parallel Ullmann coupling reaction of bromaminic acid with aniline derivatives in solution using a compact parallel synthesizer. The products were purified by HPLC and evaluated as antagonists at mouse and human P2Y(2) receptors. 4-Phenylamino-substituted 1-amino-2-sulfoanthraquinones, for example, 1-amino-4-(2-methoxyphenyl)-2-sulfoanthraquinone (PSB-716), were potent P2Y(2) antagonists with IC50 values in the low micromolar range. (C) 2007 Elsevier Ltd. All rights reserved.
• ANTHRAQUINONE COMPOUNDS AND THEIR USES
  申请人：Dundalk Institute of Technology

  公开号：EP2616449A1

  公开（公告）日：2013-07-24
• Anthraquinone Compounds and Their Uses
  申请人：McHale Noel

  公开号：US20130296588A1

  公开（公告）日：2013-11-07

  The present invention relates to a compound comprising a substituted or unsubstituted anthraquinone, or a salt or isomer thereof, for use in treating a disorder caused by or associated with dysfunctional ion channel activity. The invention finds utility in the treatment of disorders associated with smooth muscle tone and contraction, such as partial hypertension; myocardial infarction; faecal incontinence; constipation; gastro oesophageal reflux; impaired gastrointenstinal passage; urinary incontinence; erectile dysfunction; and asthma.